fibaworldcupqualifiersasia2023| Aidi Pharmaceutical: In 2023, revenue will increase by nearly 70% and HIV business will grow strongly

Newsletter summary

Eddie Pharmaceutical: revenue increases by nearly 70% in 2023 HIV business grows strongly Securities Times Web NewsFibaworldcupqualifiersasia2023Eddie Pharmaceutical released its 2023 annual report on the evening of April 15. According to the report, the company realized operating income 4.Fibaworldcupqualifiersasia2023.11 billion yuan, an increase of 68.44% over the same period last year; the company realized the net profit attributed to the shareholders of the listed company.

Text of news flash

Adi Pharmaceutical: revenue increased nearly 70% in 2023 HIV business growth strong Securities Times News, Eddie Pharmaceutical released its 2023 annual report on the evening of April 15. According to the report, the company achieved an operating income of 411 million yuan, an increase of 68.44% over the same period last year. The net profit attributed to shareholders of the listed company was a loss of 76.0695 million yuan, a decrease of 38.70% over the same period last year. The company's HIV innovative drug sales, urokinase and general medicine sales revenue have achieved rapid growth compared with the same period. During the reporting period, the total sales revenue of Adi Pharmaceutical's HIV new drugs was about 73.5788 million yuan, an increase of 119.67 percent over the same period last year. It is understood that in December 2023, the company's second innovative drug, the first domestic oral single-tablet compound class 1 innovative drug in the field of anti-HIV treatment, successfully passed the health insurance negotiation and was successfully included in the National basic Medical Insurance, Industrial injury Insurance and Maternity Insurance Drug catalogue (2023), and the contract of Enovelin tablets (Abinde?) was also successfully renewed. At the same time, the scope of health insurance payment for the two drugs is adjusted to "limited HIV infection", which will help to improve the affordability and accessibility of patients, and further promote the sales and marketing of the above-mentioned drugs. it is of great significance to the business and development of the company. The number of new patients began to rebound from November 2023. As of the date of disclosure of the annual report, the number of new patients using enovirin tablets and enomitie tablets increased significantly, the medication viscosity increased, and the accumulation of patients showed a "snowball" growth. In addition, the company has also laid out a new chemical structure of HIV integrated chain transfer inhibitor ACC017 tablets. At present, the application for domestic production of drugs in clinical trials has been approved and has entered the Ⅰ phase clinical trials. It is worth mentioning that, combined with the changes in the general environment of new drug research and development and the development of its own business, new drug research and development will focus more on the two major areas of anti-HIV and human protein, with a total investment of 84.1822 million yuan in 2023, accounting for 20.46% of business income. At present, the company's core products under research include 8 class 1 new drugs and 4 class 2 new drugs, covering anti-HIV non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, long-acting drugs, inflammation, stroke and other therapeutic fields, some of which are innovative varieties that fill the domestic gaps, have remarkable curative effects and have good market prospects, covering preclinical, phase I clinical, NDA and other stages, forming a reasonable echelon. Provide long-term momentum for the company's sustainable development. Southwest Securities believes that Aidi Pharmaceutical is in the vanguard of new anti-HIV drugs, the first domestic triple single-tablet compound anti-AIDS class 1 new drug has excellent efficacy and safety, and is expected to be released quickly after it is included in health insurance. Proofread: Li Lingfeng

Tags:

Prev: avetreelslx63| U.S. 10-year bond yields rise to 4.55% inflation and tensions in the Middle East double attack
Next: onlinebaccaratrealmoney| Serious imbalance! Federal Reserve chairman says housing market problems are 'unsolvable'